Tumor-infiltrating lymphocyte therapy: therapeutic advances and prospects
Tumor-infiltrating lymphocyte (TIL) therapy has evolved from a pioneering experimental approach to a clinically validated treatment strategy, underscored by the recent approval of lifileucel (Amtagvi) by the Food and Drug Administration (FDA) for advanced melanoma refractory to existing therapies. I...
Gorde:
| Egile Nagusiak: | , , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
EDP Sciences
2025-01-01
|
| Saila: | Visualized Cancer Medicine |
| Gaiak: | |
| Sarrera elektronikoa: | https://vcm.edpsciences.org/articles/vcm/full_html/2025/01/vcm20250003/vcm20250003.html |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|